Nicotine Replacement Therapies

Phase 3Small molecule

Nicotine Replacement Therapies is one of 28 small molecule programs targeting Tobacco Use Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tobacco Use DisorderNot yet recruiting

Smoking CessationRecruiting

Cigarette UseNot yet recruiting

Tobacco Use DisorderPreclinical

Not yet recruiting

Smoking CessationPhase 3

Recruiting

Cigarette UsePhase 3

Not yet recruiting

Competition

Competitive Landscape

34 competitors in Smoking Cessation

#DrugCompanyPhaseTrials

Nicorette

Pfizer

Approved

70 2

Chantix

PPrism Pharmaceuticals

Approved

70 3

Wellbutrin

GGlaxo Dba Glaxosmithkline

Approved

31 4

Viagra

VViatris Specialty LLC

Approved

1 5

Lunesta

Akero Therapeutics

Approved

1 6

Nicotine Free Cigarettes

Pfizer

Phase 3

28 7

Wellbutrin

GSK

Phase 3

5 8

Inderal

WWyeth-Lederle Vaccines

Approved

—9

Belsomra

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Nicotine Replacement

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Smoking Cessation

NCT05154669

Q2 2028

PreclinicalNot yet recruiting

Tobacco Use Disorder

NCT07722832

ApprovedNot yet recruiting

Cigarette Use

NCT07786896

Clinical

Trials by Indication[1]

Smoking Cessation2 trials

Effectiveness of Various Smoking Cessation Therapies in Reducing Smoking in Adolescents - 1

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 2·NCT00158171·128 enrolled

Integrating Financial Coaching and Smoking Cessation Coaching

Recruiting·NNYU Langone Health·Phase 3·NCT05154669·488 enrolled

Buprenorphine1 trial

A Pilot Text Messaging Intervention to Reduce Smoking in Office-based Buprenorphine and Inpatient Detoxification Patients

Completed·NNYU Langone Health·N/A·NCT02665208·203 enrolled

Cigarette Use1 trial

Evaluation of Dependence and Nicotine Replacement Therapy-Supported Cessation Efforts Among Regular Electronic Cigarette Use

Not yet recruiting·WWest Virginia University·Approved·NCT07786896·100 enrolled

Tobacco Use Disorder1 trial

Evaluation of the Impact of the QUITOXIL® System on Smoking Cessation in Patients With Tobacco Use Disorder : a Randomized Controlled Clinical Trial.

Not yet recruiting·KKLAVA Innovation·Preclinical·NCT07722832·606 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Nicotine Replacement Therapies. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nicotine Replacement Therapies compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nicotine Replacement Therapies. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NYU Langone Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNYU Langone Health

Nicotine Replacement Therapies

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Trials by Indication[1]

Smoking Cessation2 trials

Buprenorphine1 trial

Cigarette Use1 trial

Tobacco Use Disorder1 trial

References

Drug Info

Quick Facts

Related News